Novo Nordisk CagriSema -15%: Study Shock Causes Stock Plunge
Novo Nordisk CagriSema misses against Tirzepatide in REDEFINE-4; stock plunges 15% in pre-market – what this means for investors.
Apple Tariff Ruling: $3.3B Opportunity and China Risk in Focus
Apple tariff ruling brings billions in potential and margin boost, but China risk and new trade tariffs remain uncertainties.
Merck Dividend Strategy Opportunity: Can It Withstand the Keytruda Patent Shock in 2028?
Merck dividend strategy in focus: Can the pipeline cushion the Keytruda patent cliff starting in 2028 for dividend hunters?
Amazon AI Investments $200B: Opportunity for AWS or Cash Flow Shock?
Amazon's $200B AI investments strain free cash flow—are AWS, advertising, and AI assistants worth the cost?
Lucid Group Turnaround: Production +104% and Saudi Opportunity
Lucid Group Turnaround: Production +104%, Saudi billions, and strict cost-cutting – is that enough for the path to profitability?
Tesla Cybertruck Opportunity: Price War, Cybercab, and Autopilot Risks
Tesla lowers Cybertruck prices, launches Cybercab, and faces Autopilot lawsuits – what does this mean for TSLA investors?